Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Schnaiter

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncotarget|February 15, 2011
Refractory chronic lymphocytic leukemia--new therapeutic strategiesAndrea Schnaiter, Stephan Stilgenbauer
Therapeutic Advances in Hematology|April 5, 2013
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemiaAndrea Schnaiter, Stephan Stilgenbauer
Hematology/Oncology Clinics of North America|April 9, 2013
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachAndrea Schnaiter, Stephan Stilgenbauer
Clinics in Laboratory Medicine|November 29, 2011
Genetics of chronic lymphocytic leukemiaAndrea Schnaiter, Daniel Mertens, Stephan Stilgenbauer
Leukemia & Lymphoma|January 18, 2013
Missing the notch in NOTCH1Sabrina J Kugler, Andrea Schnaiter, Stephan Stilgenbauer, et al.
Anticancer Research|August 19, 2007
Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiationCarsten Nieder, Andrea Schnaiter, Wolfgang A Weber, et al.
Cancer Research|November 19, 2009
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemiaSandra Loeder, Thorsten Zenz, Andrea Schnaiter, et al.
International Journal of Cancer|June 23, 2015
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemiaDaniela Opel, Andrea Schnaiter, Dagmar Dodier, et al.
International Journal of Radiation Oncology, Biology, Physics|April 4, 2006
Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunctionNicolaus Andratschke, Andrea Schnaiter, Andrea Schnaitera, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncotarget|February 15, 2011
Refractory chronic lymphocytic leukemia--new therapeutic strategiesAndrea Schnaiter, Stephan Stilgenbauer
Therapeutic Advances in Hematology|April 5, 2013
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemiaAndrea Schnaiter, Stephan Stilgenbauer
Hematology/Oncology Clinics of North America|April 9, 2013
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachAndrea Schnaiter, Stephan Stilgenbauer
Clinics in Laboratory Medicine|November 29, 2011
Genetics of chronic lymphocytic leukemiaAndrea Schnaiter, Daniel Mertens, Stephan Stilgenbauer
Leukemia & Lymphoma|January 18, 2013
Missing the notch in NOTCH1Sabrina J Kugler, Andrea Schnaiter, Stephan Stilgenbauer, et al.
Anticancer Research|August 19, 2007
Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiationCarsten Nieder, Andrea Schnaiter, Wolfgang A Weber, et al.
Cancer Research|November 19, 2009
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemiaSandra Loeder, Thorsten Zenz, Andrea Schnaiter, et al.
International Journal of Cancer|June 23, 2015
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemiaDaniela Opel, Andrea Schnaiter, Dagmar Dodier, et al.
International Journal of Radiation Oncology, Biology, Physics|April 4, 2006
Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunctionNicolaus Andratschke, Andrea Schnaiter, Andrea Schnaitera, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 2